Kintara Therapeutics Inc (KTRA) has released an update.
Kintara Therapeutics is expanding its REM-001 clinical study in cutaneous metastatic breast cancer to include patients treated with pembrolizumab, with the aim of increasing enrollment and advancing to a Phase 3 trial. The study, supported by a $2.0 million NIH grant, seeks to evaluate the efficacy and optimize the design of its photodynamic therapy, which has shown promising results in previous trials. Kintara continues to focus on developing novel cancer therapies and maximizing shareholder value.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
